The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies
- Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit
- Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design
- Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates